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Abstract
Background: Adipose-Derived Stromal Cells have been shown to have multiple lineage differentiation properties
and to be suitable for tissues regeneration in many degenerative processes. Their use has been proposed for the
therapy of joint diseases and tendon injuries in the horse. In the present report the genetic manipulation of Equine
Adipose-Derived Stromal Cells has been investigated.
Results: Equine Adipose-Derived Stromal Cells were successfully virally transduced as well as transiently and stably
transfected with appropriate parameters, without detrimental effect on their differentiation properties. Moreover,
green fluorescent protein alone, fused to neo gene, or co-expressed as bi-cistronic reporter constructs, driven by
viral and house-keeping gene promoters, were tested. The better expressed cassette was employed to stably
transfect Adipose-Derived Stromal Cells for cell therapy purposes. Stably transfected Equine Adipose-Derived
Stromal Cells with a heterologous secreted viral antigen were able to immunize horses upon injection into the
lateral wall of the neck.
Conclusion: This study provides the methods to successfully transgenize Adipose-Derived Stromal Cells both by
lentiviral vector and by transfection using optimized constructs with suitable promoters and reporter genes. In
conclusion these findings provide a working platform for the delivery of potentially therapeutic proteins to the site
of cells injection via transgenized Equine Adipose-Derived Stromal Cells.
Background
Defects of the cartilage, as well as of tendons, have been
known to be poor healing injuries, which treated by
conventional surgical or pharmacological methods often
do not lead to complete structural and functional tissue
recovery and regeneration. For this purpose, transplanta-
tion of autologous or allogeneic pluripotent or termin-
ally-differentiated cells that are expanded ex vivo have
been attempted to cure such defects [1]. The majority of
research concerning mesenchymal stem cells (MSC) has
been done on rodents or humans. Small experimental
animals can be used to research the principles of stem
cell transplantation therapy, but prior to transferring
this technology to the therapy it is important to
introduce it to a large-animal model, which is bio-
mechanically more relevant to humans. Athlete equines
are considered valuable large-animal experimental mod-
els for osteoarticular and tendon disorders, since most
of them can be considered similar to the corresponding
human pathologies with regard to pathogenetic mechan-
isms and clinical outcomes. As a consequence, the appli-
cation of cell therapy in the horse has attracted
considerable interest not only as a new therapeutic
approach for equine musculoskeletal diseases but also
because it can provide numerous inputs for making pro-
gress in clinical application of MSC to human medicine,
especially in musculoskeletal health problems [2]. Joint
disease, and specifically osteoarthritis (OA), is one of the
most prevalent and debilitating diseases affecting both
humans and horses. The equine as animal model is a
potential donor of relatively large amounts of tissue and
cells, and consequently leads to sufficient yield of
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them in numerous in vitro and in vivo experiments.
Some of the challenges in stem cell research are the
expansion, propagation, and genetic manipulation of
functional adult stem cells. The clinical application of
neural stem cells will be limited by logistic and ethical
problems associated with their isolation and by potential
immunologic incompatibility due to the requirement for
allogeneic transplantation. On the contrary, adult stem
cells derived from mesodermal sources, such as bone
marrow and adipose tissue, can be obtained from
patients with greater ease and because autologous trans-
plantation obviates immunologic incompatibilities.
Although most of the pioneering studies have been
performed on bone marrow-derived MSC, recently adi-
pose tissue has attracted interest as a source of multipo-
tent cells for therapeutic applications. Adipose tissue is
ubiquitous and uniquely expandable. Most patients pos-
sess excess fat that can be harvested making adipose tis-
sue an ideal source for clinical research. Adipose-
Derived stromal cells (ADSCs) have been examined as
an alternative to bone marrow stromal cells and have
been shown to be comparable [3]. Here, the transient
and stable genetic manipulation of Equine ADSCs
(EADSCs) using viral and non viral systems was evalu-
ated, thus providing the proof of principle of the ability
of EADSCs to potentially deliver bio-active factors in a
paracrine manner to the site of the cell injection; more-
over, the secreted antigen could metastatically, i.e. by
blood stream, be delivered to other body sites following
cell homing.
Results
hCMV promoter is strongly activated in EADSCs
Although epigenetic regulation of a transgene is very
important, transgene transcription is strongly depen-
dent on the type of promoter employed to drive the
expression of a desired monocistronic or polycistronic
open reading frame (ORF). Therefore, several promo-
ters were tested in a transient transfection assay. To be
able to quantify promoters transactivation by the pool
of transcription factors made by EADSCs, Herpes Sim-
plex Virus Timidine Kinase (HSV-TK), Phosphoglycer-
okinase (PGK), Simian Virus 40 (SV40), Bovine
Herpesvirus 4 Immediate Early (BoHV-4 IE2) and
human Cytomegalovirus Immediate Early (hCMV) pro-
moters were sub-cloned in front of the pGL3 vector
luciferase reporter gene. The generated constructs (Fig.
1), as well as pGL3 empty vector, used as a control,
were co-transfected with pTK-Renilla for data normali-
zation into EADSCs. Twenty-four hours post-transfec-
tion, cells were lysed and luciferase activity was
measured. hCMV gave the best expression (Fig. 1A),
thus it was used for further experiments. Although this
experiment gave good information about the type of
promoter better transactivated by EADSCs transcrip-
tional machinery, no information could be achieved in
terms of efficiency of transfection, which is tightly
dependent on the method employed to transfect cells.
Efficiency of transfection of EADSCs was measured
comparing 3 different methods of transfection.
EADSCs were transfected by calcium phosphate preci-
pitation, lipofection and electroporation with pEGFP-
C1 plasmid containing the hCMV promoter, which
was shown to be nicely activated into EADSCs, and
the enhanced green fluorescent protein (EGFP) as a
reporter gene. Transfected cells were analyzed at 48 h
p o s tt r a n s f e c t i o nb yf l u o r e s c e n c em i c r o s c o p ya n df l o w
cytometry for EGFP-expressing cells and the ratio
between transfected and untrasfected cells was calcu-
lated on the base of three repeated experiments. Elec-
troporation gave the best efficiency of transfection,
reaching the ~95%, respect to calcium phosphate pre-
cipitation and lipofection (Fig. 1B).
Viral transduction of EADSCs keeps stable transgene
expression following differentiation
EADSCs labelling is a very important issue when cell fate
in terms of differentiation, bio-distribution and engraft-
ment need to be monitored in vivo. As a first attempt to
transgenize EADSCs, two different viral vectors were
employed: a self-inactivating replicating incompetent
third generation lentiviral vector [4,5] expressing EGFP
under the control of hCMV promoter and a newly devel-
oped bovine herpesvirus 4 (BoHV-4)-based vector [6]
expressing EGFP under the control of hCMV promoter.
EADSCs were infected with bothv e c t o r sa n de f f i c i e n c y
of transduction was monitored at 24 and 48 h post infec-
tion. Although both viral vectors transduced EADSCs
with a very high efficiency, 99.7% for the BoHV-4-based
vector (Fig. 2A and 2C) and 99.92% for the lentiviral vec-
tor (Fig. 2B and 2E) respectively, EADSCs were highly
permissive for BoHV-4-based vector replication. In fact, a
strong cytopathic effect (CPE) developed in EADSCs as
far as 48 h post BoHV-4-based vector infection, leading
to an high cell free virus titer (Fig. 2D). Lentiviral trans-
duced EADSCs were grown for 15 passages, transgene
was constantly expressed for all passages tested (Fig. 3A),
and differentiating properties were maintained when
EADSCs were induced to differentiate with osteogenic
medium (Fig. 3B). The state of differentiation was con-
firmed with both alizarin and von Kossa staining (Fig. 4).
Stably transfected EADSCs keep transgene expression
following drug selection and differentiation
Starting from the assumption that the hCMV promoter
was the best promoter to drive the expression of an het-
erologous gene in EADSCs and that electroporation was
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ble combination between a reporter gene and a select-
able marker integrated into the same vector to stably
label and select EADSCs was investigated.
As a selectable marker, the neo gene (Aminoglycoside
3’-phosphotransferase), due to its low toxicity and large
window of concentration, was used. Whereas EGFP, due
to its high stability and direct detectability in living cells,
was employed as a reporter gene. Although EGFP and
neo could be used as two independent expression cas-
settes integrated into the same vector, this kind of
approach could not guarantee EGFP and neo simulta-
neous expression. G418 drug selection could favour neo
expression respect to EGFP, leading to a certain number
of stably transfected, G418-resistant but not green
EADSCs. Therefore, two different strategies were
applied. First, an expression vector, pCMV-EGFP/neo
(Fig. 5B), was generated by fusing the EGFP ORF in
Figure 1 P r o m o t e r sa c t i v a t i o ni nE A D S C s . A) Transiently transfected EADSCs with constructs containing promoter in front of the luciferase
reporter gene or pGL3 empty vector (diagrams not on scale) as a control, at 24 h post transfection. The results are expressed as the mean
relative Luciferase units after normalizing with efficiency of transfection. Each reaction was done in quadruplicate, and each point represents the
average ± standard deviation from three experiments. B) Efficiency of EADSCs transfection obtained with different transfection methods, using
pEGFP-C1 as a reporter plasmid. Each transfection method was done in quadruplicate, and each point represents the average ± standard
deviation from three experiments. EGFP was monitored by fluorescence microscope and quantified by flow cytometry.
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ter. A second expression vector, pCMV-EGFP-IRES-neo
(Fig. 5C), containing an Internal Ribosomal Entry Site
(IRES) that allows the simultaneous translation of two
proteins (in the present case EGFP and neo) from a sin-
gle transcript, was generated. Equal number of EADSCs
were electroporated (see materials and methods) with
equal amounts of pCMV-EGFP/neo, pCMV-EGFP-IRES-
neo and pSP72 (a vector lacking both EGFP and neo)a s
a mock-transfected control. Following electroporation,
cells were left to recover overnight and drug selection
was applied with 400 μg of G418/ml of complete med-
ium. Selected G418-resistant cells were counted when
all mock-electroporated EADSCs died (Fig. 5A). As
s h o w ni nF i g .5 Ba n d5 C ,p C M V - E G F P / neo leaded to a
higher number of both G418 resistant and green
E A D S C s ,c o m p a r e dt oE A D S C se l e c t r o p o r a t e dw i t h
pCMV-EGFP-IRES-neo (Fig. 5B and 5C). Furthermore,
pCMV-EGFP/neo stably transfected EADSCs maintained
osteogenic properties as well as EGFP expression when
induced to differentiate (the experiments were repeated
for three times, giving similar results) (Fig. 5D). State of
differentiation was confirmed with both alizarin and von
Kossa staining (Fig. 6). Thus, electroporated GFP/neo
fusion peptide along with hCMV promoter could be
considered an efficient and versatile system to generate
stably labelled EADSCs to be used in vivo.
Paracrine delivery of secreted protein by transgenized
EADSCs in vivo
Taking into account EADSCs capability to stably allo-
cate a transgene in vitro without detrimental effect on
their physiology, such characteristic was further investi-
gated in vivo.
As a general method to demonstrate the capability of
transgenized EADSCs to deliver a potential secreted fac-
tor, an immunodominant secreted antigen previously
shown to elicit a strong immune response was adopted
[7]. EADSCs were transfected with a construct, pSecE2
[7], expressing the viral secreted antigen Bovine Viral
Diarrhea Virus glycoprotein E2 (BVDV gE2) and
EADSCs stably expressing the secreted antigen (gE2-
Figure 2 Viral transduction of EADSCs. Phase contrast and fluorescence representative images (20×) of BoHV-4-based vector transduced
EADSCs at 24 and 48 h post infection (P.I.) (A), along with the transduction efficiency measured by flow cytometry (C) and the viral titer
measured at 24 and 48 h post infection (hs P.I.) (D). In B, representative images of lentiviral vector transduced EADSCs at 24 h post infection and
respective transduction efficiency measured by flow cytometry (C).
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(Fig. 7A). Immediately after the collection of the preim-
mune serum, 3 horses were intramuscularly inoculated
with 3 × 10
6 gE2-EADSCs. An identical inoculation was
performed 2 weeks later. Blood samples were collected
at 2 weeks following each inoculum from all animals for
the assessment of antibodies against BVDV gE2.
Furthermore, body temperature and development of any
adverse reaction to the inoculum were monitored daily.
None of the animals developed fever or other clinical
signs during the time of observation (4 weeks). All ani-
mals developed a serum neutralizing antibody response
against BVDV, detectable the fourth week after the first
viral inoculation (Fig. 7B). It was therefore possible to
conclude that EADSCs were able to express and deliver
an exogenous secreted factor, in the present case a viral
antigen, able to elicit the humoral immune response
into the inoculated animals.
Discussion and Conclusions
Adipose-derived cells differentiate into several cell types
[9]. Although it is not clear if a single adipose-derived
cell can differentiate into all of these lineages, in differ-
ent labs ADSCs clones expressing four cell lineages
(adipo-, chondro-, osteo-, and neuro-) [10] have been
generated, thereby demonstrating the presence of multi-
potent and oligopotent cells within adipose tissue. Self-
renewing and multipotent adipose-derived progenitor
and stem cells have been shown to be the ideal candi-
dates for the generation of induced pluripotent stem
(iPS) cells by transduction with four standard repro-
gramming factors, c-Myc, Klf4, Oct4, and Sox2 [11],
[12]. Moreover, ADSCs exhibit high intrinsic expression
of self-renewal supporting factors and can effectively
s e r v ea sf e e d e rl a y e r so ft h e i ro w no ra si n d e p e n d e n t
pluripotent cells [11], [12]. Since Equine iPS (EiPS) have
not been generated so far, methods to genetically
manipulate EADSCs would be of great interest for a
future generation of EiPS. Therefore, the genetic manip-
ulation of EADSCs represents a prerequisite for the
above-listed purposes.
Transcriptional activity of different promoters was
tested by dual luciferase reporter assay and hCMV pro-
moter was proven to be the better transcribed by
EADSCs. Although gene delivery was achieved with
high efficiency by a VSV-G pseudo-typed self-inactivat-
ing replicating-incompetent third-generation lentiviral
vector, as well as by BoHV-4-based vector, a safer physi-
cal method to stably transfect EADSCs was assessed, to
avoid the concerns attributed to the use of integrating
Figure 3 Viral transduction of EADSCs maintains transgene expression. Representative phase contrast and fluorescence images (20×) of
undifferentiated (A) and differentiated (B) EADSCs at 3, 9 and 15 passages post lentiviral vector transduction.
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known that integrating lentiviral vectors could lead to
insertional mutagenesis, whereas the un-integrating
BoHV-4 induced a strong cytopathic effect on EADSCs
due to high viral replication. Therefore, electroporation
with optimized parameters was employed and shown to
be as good as viral transduction in term of gene delivery
efficiency. Moreover, successfully transduced or trans-
fected EADSCs maintained their differentiating capabil-
ity when induced to differentiate toward the osteogenic
lineage. Osteogenic differentiation property is widely
accepted as the biological read-out for the differentiation
of cells with a mesenchymal derivation, as is the case for
EADSCs.
Expressing multiple transgenes within the same target
EADSCs could be required for multiple gene transfer
and EADSCs-based therapy application as well as for
tracking EADSCs engraftment and differentiation within
a specific area of the animal body. Gene function studies
are best performed by expressing cDNAs together with
a marker gene; by means of this approach, genetically
modified EADSCs can be identified in vitro and in vivo.
Similarly, transgenized EADSCs-based therapy applica-
tions can be improved by purification of gene-corrected
EADSCs before in vivo administration, taking advantage
of coordinate expression of drug selectable markers or
living colour reporter genes. Coordinate expression of
more than one transgene in EADSCs is essential when
the activity to be reconstituted by gene transfer depends
on multiple subunits encoded by different genes, or
requires the synergism of separate molecules. The co-
expression of neo and EGFP as a fusion protein (EGFP/
Figure 4 Viral transduction of EADSCs maintains differentiation properties. Representative images (20×) of von Kossa and alizarin stained
differentiated EADSCs at different passages (3, 9 and 15) post lentiviral transduction.
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Page 6 of 12Figure 5 Generation of stably transfected EADSCs. A) Flow chart of the method used to obtain a homogeneous population of EGFP stably
labelled EADSCs by electroporation and drug selection. Phase contrast and fluorescence representative images (20×) of green G418-selected
EADSCs generated with pCMV-EGFP/neo fusion peptide (B) and pCMV-EGFP-IRES-neo bicistronic vector (C) (diagram not on scale beside the
images). D) Generating efficiency of green G418 selected EADSCs obtained with pCMV-EGFP/neo and pCMV-EGFP-IRES-neo respectively and
compared to mock-transfected EADSCs. Each experiment was done in quadruplicate, and each point represents the average ± standard
deviation from three experiments. Green G418 EADSCs were monitored by fluorescence microscope and quantified by flow cytometry. E) Phase
contrast and fluorescence representative images of differentiated stable green G418 selected EADSCs obtained with pCMV-EGFP/neo.
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EADSCs were simultaneously labelled and selected in a
stable form and with high efficiency, compared to the
inefficient IRES strategy, in which re-initiation of the
translation of the second cistron, in this case the neo
ORF, was highly inefficient and leaded to a low number
of drug selected EADSCs. However, a further alternative
approach could be employed, which is based on 2A self-
cleaving peptides of the Foot and Mouth Disease Virus
(FMDV) and other picoRNA-viruses [13]; however,
application of this technology has been limited until
recently because it requires molecular engineering of
both transgenes and introduces sequence changes that
may affect the activity, stability and immunogenicity of
their protein product.
MSCs that act as Trojan horses to deliver therapeutic
factors could be one step forward to gene delivery in
suitable diseases, for instance joint- and teno-ligament
disorders and EADSCs seem to have all the characteris-
tics for such kind of objective. As a matter of fact, stably
transfected EADSCs with secreted antigen were able to
immunize horses when EADSCs were intramuscularly
injected, showing that any kind of potentially therapeu-
tic secreted factor could be delivered by EADSCs upon
transgenesis. For instance, neurotrophic and trophic fac-
tors (such as brain-derived neurotrophic factor, glial cell
line-derived neurotrophic factor (GDNF), ciliary neuro-
trophic factor, vascular endothelial-derived growth fac-
tor, insulin-like growth factor-1 (IGF-1) and Bone
Morphogenic Proteins (BMPs) have been demonstrated
promising in recovery or delaying the onset of many dis-
eases [14]. In the same manner, the use of phage dis-
play-based single-chain miniantibodies (scFvs), which
are small and consist of a single fusion polypeptide, has
been applied. ScFvs are often derived from natural or
synthetic cDNA libraries, but they can also be engi-
neered from the sequences encoding the variable regions
of individual hybridomas. In the latter case, scFvs retain
the antigen binding properties of the parent monoclonal
antibody [15]. However, clinical trials using neuro-
trophic factors or scFvs have been unsuccessful thus far
because of problems with drug pharmacokinetics, dose-
limiting toxicities and the potential for antibody inacti-
vation. Therefore, significant efforts have focused on
optimal delivery methods for these factors. Several
studies have investigated pump-based delivery of recom-
binant proteins or direct gene delivery by viral and non-
viral vectors, although with contrasting results, thus the
transplantation of EADSCs expressing these factors
could represent an alternative and possibly winning
strategy. Interestingly, many works demonstrated that
ADSCs not genetically-altered to express specific factors
also showed a trend for increased neuromuscular func-
tion and increased survival, potentially through trophic
factors that ADSCs themselves naturally provide [16],
[17]. Further study of EADSCs based on these results is
certainly warranted to advance their clinical application
in individuals with specific diseases, as is the case of
joint diseases and tendon injuries in horses. However,
several key questions remain open: how many injections
will be needed in a patient? Will the therapy be a one-
time delivery? Will the cells survive, integrate, and
express for long periods of time in animal tissues? Will
the cells migrate to other organs? In any case, this work
represents an additional step for the development of
therapeutic approaches for cell-based therapy in the
horse itself and in the horse as a model for human
diseases.
Methods
ADSCs preparation
Cells preparation was performed as previously described
with minor modifications [18]. Adipose tissue (approxi-
mately 15-20 grams) was collected from intra-abdominal
fat deposit or supragluteal subcutaneous region of adult
horses at the abattoir immediately after slaughtering.
Tissue was minced into small pieces under sterile condi-
tions and washed several times with phosphate buffer
saline solution (PBS) containing penicillin (1,000 IU/ml)
and streptomycin (100 mg/ml) (Sigma-Aldrich Corp.,
ST. Louis, MO, USA). The tissue was then digested with
7.5 mg/ml type I collagenase (Sigma-Aldrich) in Dulbec-
co’s modified Eagle’s medium low glucose (DMEM)
(Lonza, Inc. Rockland, ME, USA) medium under mild
shaking for 1 hour at 37°C. After digestion, the remain-
ing tissue fragments were removed, cells suspension was
filtered through a 50 μm nylon mesh and centrifuged at
250 × g for 10 minutes. The supernatant was removed
and the cell pellet resuspended in DMEM containing
10% v/v fetal bovine serum (FBS) (Lonza), 1,000 IU/ml
penicillin and 100 mg/ml streptomycin. Finally cells
were diluted to 5.0 ×10
4 cells/cm
2 in culture medium,
seeded in 25 cm
2 tissue culture flasks and incubated at
Figure 6 Stably transfected EADSCs maintains differentiation
properties. Representative images (20×) of von Kossa and alizarin
stained stable green G418 selected EADSCs obtained with pCMV-
EGFP/neo.
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Page 8 of 12Figure 7 Paracrine delivery of secreted protein by transgenized EADSCs in vivo. A) Western immunoblotting at 24, 48 and 72 h of gE2-
EADSCs conditioned medium and compared to 72 h conditioned medium coming from mock-transfected and selected EADSCs. B) Humoral
immune responses of 3 horses (1, 2 and 3) inoculated with gE2-EADSCs. Preimmune sera (time 0), sera at 2 weeks post gE2-EADSCs inoculation
(time 2) and sera at 4 weeks post gE2-EADSCs inoculation (time 4 or time 2 from the second post gE2-EADSCs inoculation). Anti BVDV
antibodies were detected by serum neutralization (SN) test. SN antibodies were expressed as the reciprocal of the highest dilution of the serum
that inhibited the development of virus-induced CPE in MDBK cells. Virus neutralization (VN) titers of >1 (log2) were considered to be positive.
Each value represents the response of each horse. Multiwells plate image with respective horse sera dilution, where crystal violet staining allows
macroscopic evaluation of the integrity (violet wells) or the destruction (clear transparent wells) of the cell monolayer. The test was repeated
three times and the same result was obtained. Controls were established in the absence of sera (-S) or with sera coming from BVDV infected
animals.
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Page 9 of 1237°C in 5% CO2. After 48 h the medium was changed
with fresh medium to remove non adherent cells; there-
after, medium was renewed every 3 days. The first sub-
culture was performed after 7-10 days. Subsequent
subcultures were performed when cells reached about
80% confluence.
Constructs design and generation
pHSV-TK luciferase, pCMV-luciferase, pSV40-luciferase,
pPGK-luciferase and pTK-renilla were obtained from
Promega (Promega Corp., Madison, WI, USA). pBoHV-4
IE2 was constructed by sub-cloning a PCR fragment, cor-
responding to the BoHV-4 Immediate Early 2 (IE2) pro-
moter in front of the luciferase reporter gene contained
into the pGL3-basic vector as previously described [19].
To obtain pEGFP-IRES-neo, the EGFP ORF was cut with
NheI and BamHI and legated into the NheI/BamHI sites
of pIRESneo2 (Clontech Laboratories Inc., Mountain
View, CA, USA). Whereas, to get pCMV-EGFP/neo,n e o
ORF was amplified with a couple of primers (neo/KpnI/
sense, 5’-cgg ggt acc atg att gaa caa gat gga ttg-3’ and
neo/KpnI/antisense, 5’-cgg ggt acc tca gaa gaa ctc gtc aag
aag-3’) and the resulting amplicon sub-cloned in frame to
the carboxy-terminal of EGFP into the pEGFP-C1 vector
(Clontech Laboratories). Whereas, pSecE2 was obtained
sub-cloning the Bovine Viral diarrhea Virus glycoprotein
E2 into the pSecTag2 vector (Invitrogen Corp., Carlsbad,
CA, USA) as previously described [7].
Dual luciferase reporter assay
Confluent EADSCs in twenty-four well plates were co-
transfected with 0.5 μg of reporter construct or 0.5 μg
pGL3 empty vector, as a negative control and 0.05 μgo f
pTK-Renilla to normalize the efficiency of transfection,
using LTX transfection reagent (Invitrogen) as suggested
by the manufacturer. Transfection mixture was prepared
in DMEM without serum and antibiotics and left on the
cells for 6 h at 37°C, 5% CO2 in air, in a humidified
incubator. After 6 h, the transfection mixture was
replaced with complete medium (RPMI-1640 (Lonza),
10% FBS, 50 IU/ml of penicillin, 50 μg/ml of streptomy-
cin and 2.5 μg/ml of Amphotericin B (Sigma-Aldrich))
and left to recover for 18 h at 37°C, 5% CO2 in air, in a
humidified incubator. Twenty-four hours post transfec-
tion, cells were analyzed for Luciferase expression.
Luciferase reporter assay was performed with a Dual
Luciferase Reporter Assay System kit (Promega) with
minor modifications. Following treatments, cells were
washed with PBS, lysed with 100 μl of lysis passive buf-
fer by freeze-thawing at -80°C. 10 μl of the cell lysate
were added to 50 μl of LAR and Luciferase activity was
determined with a PerkinElmer Victor
3 Multilabel
Counter (PerkinElmer, Waltham, MA, USA), according
to the manufacturer’s specifications. Individual assays
were normalized for Renilla activity with a second read-
ing, adding 50 μl of Stop & Glo substrate (Promega).
Experiments were performed with 4 replicates at each
time point and each experiment repeated three times.
Statistical differences were tested by ANOVA.
EADSCs transfection
Lypofection: was performed using LTX transfection
reagent (Invitrogen) as suggested by manufacturer and
described above, the only difference was that reagents
were scaled-up to 25 cm
2 flasks. Calcium phosphate pre-
cipitation: was performed as previously described by
others [20]. Electroporation: EADSCs were sub cultured
to a fresh 25 cm
2 flask when growth reached 90% con-
fluence and were incubated at 37°C in a humidified
atmosphere of 95% air-5% CO2. Plasmid DNA (5 μg) in
600 μl DMEM without serum was electroporated (Equi-
bio apparatus, Wolf Laboratories Limit., York, UK), 186
V, 960 μF, 4-mm gap cuvettes (Wolf Laboratories)) into
EADSCs. Electroporated cells were returned to a new
flask containing complete medium.
Stable transfection
EADSCs were electroporated as described above. Elec-
troporated cells were returned to the flask, fed the next
day with complete medium supplemented with 400 μg/
ml of G418 (Sigma-Aldrich) and split 1:2 when they
reached confluence at 2 days post electroporation. Cells
were grown till complete selection.
BoHV-4-based vector preparation, infection and recovery
assay
Infection of EADSCs was performed with 1 MOI (multi-
plicity of infection) of BoHV-4EGFPDTK, which was
propagated as previously described [21]. A BT cell line
(bovine turbinate cells, ATCC, CRL-1390, LGC Stan-
dards S.r.l., Milano, Italy) was used to propagate the
virus, because of its high sensitivity towards infection of
BoHV-4. BT cells were cultured in DMEM containing
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and
100 μg/ml streptomycin, and incubated at 37°C in a
humidified atmosphere containing 5% CO2.B o H V -
4EGFPDTK was propagated by infecting confluent
monolayers with 1 of 50% tissue culture infective dose
(TCID50) per 5 cells. After 4 days, cultures were frozen
and thawed three times to release the virus. After
removal of cell debris by low-speed centrifugation, the
TCID50 was determined by limiting dilution. Virus stock
thus obtained was stored at -80°C.
Cell cultures in six-well plates were infected with virus
at a MOI of 10 TCID50/cell for 1 h. After infection, the
inactivation of extracellular virus was carried out by
low-pH treatment [22]. Briefly, the medium was
r e m o v e da n dt h ep l a t e sw e r ew a s h e do n c ew i t hP B S ,
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plates) or a buffer (pH 3) containing 40 mM citric acid
(Sigma-Aldrich), 10 mM KCl (Sigma-Aldrich), and 135
mM NaCl (Sigma-Aldrich). This procedure completely
inactivated the absorbed non-penetrated infectious parti-
cles. Cultures were washed with medium and cultured
till CPE completely destroyed the cell monolayer, after
which 1 ml of the medium was removed from each well
and centrifuged for 5 min at 1000 × g in a bench-top
centrifuge to remove any cellular debris. TCID50 were
determined on MDBK cells by limiting dilution.
Lentiviral vector preparation and transduction of EADSC
Third generation of lentiviral vector were prepared as
previously described [23]. Seventy-five cm
2 flasks of 293T
cells were transfected by calcium-phosphate precipitation
based method. Two hours before transfection, growing
media (DMEM, 10% FBS, 50 IU/ml of penicillin, 50 μg/
ml of streptomycin and 2.5 μg/ml of Amphotericin B)
were changed with the fresh ones and four plasmids
DNA transfection mix were prepared by adding 9 μgo f
envelope plasmid (pMD2-VSVG), 12.25 μg of core packa-
ging plasmid (pMDLg/pRRE), 6.25 μg of REV plasmid
(pRSV-REV) and 25 μg of transfer vector (pCCLsin18.
PPT.Prom.GFP.Wpre). The plasmid solution was made
up to a final volume of 500 μl with 450 μlo fH 2Oa n d5 0
μlo f2 . 5MC a C l 2 (Sigma-Aldrich). The precipitate was
formed by drop wise addition of 500 μlo ft h e2 ×H B S
solution (280 mM NaCl (Sigma-Aldrich), 100 mM
HEPES (Sigma-Aldrich), 1.5 mM Na2HPO4 (Sigma-
Aldrich), pH 7.12) to the 500 μl plasmid DNA-CaCl2 mix
and finally added to the 293T cells. The Ca-Phosphate-
DNA precipitate was allowed to stay on the cells for 14-
16 h, after which the medium was replaced with 10 ml of
fresh medium. Forty-eight hours after changing the
media, the cell supernatant containing viral particles was
collected, centrifuged at 500 × g for 5 minutes, filtered
through a 0. 22 μm nitrocellulose filter, aliquoted and
stored at -80°C. Transducing units on ml (TU/ml), were
determined by limiting dilution on 293T cells.
EADSCs were plated on 25 cm
2 flasks and grown till
they reached 80% (~ 10
6 cells) of confluence. The lenti-
viral vector was added onto each flask at an MOI of 1.
EADSCs were incubated overnight at 37°C and then the
media was replaced with 5 ml of fresh media. After 2
days of incubation, cells were analyzed for EGFP expres-
sion under a fluorescence microscope or flow cytometry.
Flow cytometry
Transfected or transduced EADSCs, were then washed
twice with PBS and 5 μl of 7-Amino-actinomycin D (7-
AAD, BD Biosciences, San Jose, CA, USA) solution were
added to asses cell death. Cells were acquired by FACSCa-
libur flow cytometer (BD Biosciences) equipped with a 15
mW Argon laser using 488 nm band pass filter, calibrated
with CALIBRITE 3 beads (BD Biosciences) and FACS-
Comp Software (BD Biosciences). Analysis were per-
formed using Cell Quest software (BD Biosciences).
ADSCs osteogenic differentiation and specific staining
For inducing osteogenic differentiation mesenchymal
stem cells were plated at a density of 5,000 cells/cm
2 in
a2 5c m
2 culture flask. When cells reached about 80% of
confluence they were treated with dexamethasone
(Sigma-Aldrich) (0.1 μM), b-glicerophospate disodium
(Sigma-Aldrich) (10 mM) and ascorbic acid (Sigma-
Aldrich) (250 μM) in DMEM with 10% FBS. After 10-15
days, osteogenic differentiation was demonstrated by
von Kossa silver reduction method and alizarin staining.
The differentiated cultures were fixed 20 minutes at
room temperature with a PBS 4% paraformaldehyde
(Sigma-Aldrich) solution. Cells were washed twice with
distilled water and then stained either with alizarin or
von Kossa method. For the von Kossa staining, the von
Kossa Bioptica kit (04-170801) (Bioptica s.p.a., Milano,
Italy) was used, as described by the supplier. Briefly,
cells were incubated subsequently in lithium carbonate
solution, silver nitrate solution, reducing solution and
sodium sulphite solution (provided by the kit) to deter-
mine the specific substitution of calcium ions by catio-
nic silver. Nuclei were counterstained with Mayer’s
Carmalum (Bioptica).
For alizarin red staining, the StemPro Osteogenesis Dif-
ferentiation kit (Invitrogen) was employed as described
by the supplier. Fixed cells were washed twice with dis-
tilled water and incubated with 2% Alizarin Red S solu-
tion (pH 4.2), provided by the kit, for 2 to 3 minutes.
Subsequently, stained cells were washed three times with
distilled water and visualized under a light microscope
and images were captured for qualitative analysis.
Western immunoblotting
Protein free cell supernatants (20 μl) were electrophor-
esed through 10% SDS-polyacrylamide gels and trans-
ferred to nylon membranes by electro-blotting.
Membranes were incubated with monoclonal anti-
B V D V - g E 2( c l o n e1 5 7 ;V R M D ,I n c . ,P u l l m a n ,U S A ) ,
probed with horseradish peroxidase-labeled anti-mouse
immunoglobulin antibody (Sigma-Aldrich), and visua-
lized by enhanced chemiluminescence (ECL Kit;
PIERCE, Rockford, IL, USA).
Serological tests
Serum neutralization tests were performed as follows.
Twenty-five microliters of each serum sample were added
to the first line of wells of 96-well plates. Twenty-five
microliters of DMEM were added to each well and, for
each serum tested, serial two-fold dilutions were made.
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Twenty-five microliters of virus suspension containing 100
TCID50 of BVDV was added to each well. After 1 h of
incubation at 37°C, 50 μl of a MDBK cell suspension were
added to each well and the plates were incubated for 3
days at 37°C in a humidified atmosphere of 95% air-5%
CO2. Expression of viral infectivity and serum neutralizing
activity through CPE were detected by microscopy and or
by crystal violet (Sigma-Aldrich) staining of the cell mono-
layer. The neutralization antibody titers were expressed as
the reciprocal (log 2) of the final dilution of serum that
completely inhibited viral infectivity.
Animal handling and care
Horses were cared for and used in accordance with Ita-
lian laws for animal experimentation. Horses were main-
tained at 24°C with a controlled light cycle (12 h of light,
starting at 6:00 a.m.) and with food and water ad libitum.
Blood samples were obtained and viral injections were
performed via the auricular vein at scheduled intervals.
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